文献速递肝病

酒精相关性肝炎的自然史与新型复合终点的开发:前瞻性多中心研究数据

Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study.
PubMed 文献 · Hepatology · 2025-09-09

基于AlcHepNet联盟1127名参与者(712例AH患者、256例无临床肝病的重度饮酒对照、159例健康对照)的前瞻性6个月随访,712例AH患者中79.0%为重度、21.0%为中度,32.5%死亡、12.1%接受肝移植,64.5%发生复合肝脏/饮酒事件;中度与重度AH的30、90、180天死亡率分别为0.7% vs 17.2%、3.4% vs 26.5%、8.8% vs 30.5%(均p<0.001)。

要点

  • AH患者6个月内复合肝脏/饮酒事件发生率达64.5%,需早期干预。
  • 重度AH的30、90、180天死亡率分别为17.2%、26.5%、30.5%,显著高于中度AH。
  • 更高MELD评分、更低平均动脉压和基线白细胞增多与90天死亡率升高相关。

核心结论

  • 大型观察性研究显示AH患者6个月内复合肝脏和饮酒事件发生率高,重申早期干预的必要性。

研究设计与样本

  • 前瞻性多中心观察性队列,纳入1127名参与者:712例AH患者、256例无临床肝病的重度饮酒对照、159例健康对照,在美国8个中心随访6个月。

主要发现

  • 712例AH患者(年龄45±10.7岁;59.1%男性)中,558例(79.0%)为重度、148例(21.0%)为中度,232例(32.5%)死亡,86例(12.1%)接受肝移植。
  • 中度与重度AH的30天死亡率分别为0.7%与17.2%,90天为3.4%与26.5%,180天为8.8%与30.5%(均p<0.001)。
  • 459例(64.5%)AH患者发生复合肝脏/饮酒事件。
  • 更高MELD评分、更低平均动脉压和基线白细胞增多与AH患者90天死亡率升高相关(均p<0.05);大学教育和较高ALP与死亡率降低相关。
  • 重度饮酒对照组死亡率低(n=3;1.2%)。

关键数值与推荐

  • 复合终点(AlcHepNet复合指数)包括死亡、肝移植、肝脏失代偿(新发/加重腹水、HE、静脉曲张出血)、肝脏相关住院、MELD增加≥5和恢复饮酒。

临床怎么用

  • 对AH患者应关注复合终点事件,包括恢复饮酒,早期识别高危患者并干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AIMS: The clinical course and outcomes of alcohol-associated hepatitis (AH) remain poorly understood. Major adverse liver outcomes do not capture the added risk of return to drinking. We examined the natural history of AH and developed a composite endpoint using a contemporary observational cohort of AH. APPROACH RESULTS: A cohort of 1127 participants: 712 AH patients, 256 heavy drinking controls without clinically evident liver disease, and 159 healthy controls, were prospectively followed for 6 months at 8 United States centers as part of the Alcoholic Hepatitis Network (AlcHepNet) consortium. Outcomes included mortality and a composite endpoint (AlcHepNet composite index) that included death, liver transplantation, hepatic decompensation (new onset/worsening ascites, HE, variceal bleeding), liver-related hospital admission, MELD increase ≥5, and return to drinking. Of 712 AH patients (age 45±10.7 y; 59.1% male), 558 (79.0%) had severe and 148 (21.0%) had moderate AH, 232 (32.5%) died, and 86 (12.1%) underwent liver transplantation. Mortality rates in moderate AH and severe AH were 0.7% versus 17.2% (30 d), 3.4% versus 26.5% (90 d), and 8.8% versus 30.5% (180 d), respectively (all p <0.001). Composite liver/alcohol use events were noted in 459 (64.5%) AH patients. Higher MELD score, lower mean arterial pressure, and baseline leukocytosis were associated with higher 90-day mortality in AH (all p <0.05). College education and higher ALP were associated with lower mortality. Heavy drinking controls had low mortality (n=3; 1.2%). CONCLUSIONS: This large observational study showed a high incidence of composite liver and alcohol-use events within 6 months, reiterating the need for early interventions.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Dasarathy S, Tu W, Welch N, et al. Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study. Hepatology. 2025. PMID: 40924794. doi:10.1097/HEP.0000000000001513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。